In gastric cancer, the Keynote-811 trial showed that pembrolizumab in combination with trastuzumab and chemotherapy improved OS in HER2-positive patients, with the greatest benefit observed in patients whose tumors expressed PD-L1 (CPS ≥1) [162]. Here, CD274 is linked to gastric cancer.